Healthcare entity
Every one of those 1 sits in a single category, market-trends. Kaveri Therapeutics is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window.
Last mentioned: Jul 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, market-trends. Kaveri Therapeutics is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window. Source depth averages 2 original sources per story, versus 2.2 across the same-window beat baseline. We currently track 1 Healthcare story that mention Dr. Robert Pierce, all published on July 27, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Dr. Robert Pierce. Shared-story counts are live from our verified record — not editorial picks.
Lupin’s creation of Kaveri Therapeutics, a U.S. oncology biotech housing two early-stage programs with positive ASCO data, signals a shift toward decentralized R&D models. The spin-out could accelerate the development of targeted cancer treatments and expand options for patients.
Source: floydct.com · thestarphoenix.com
Dr. Robert Pierce is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
